Αποτελέσματα Αναζήτησης
21 Φεβ 2023 · These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program. The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023 in Seattle.
- Gileads Innovative HIV Treatment Research Pipeline Aims to Address ...
Gilead researchers have developed 12 HIV medications,...
- Gileads Innovative HIV Treatment Research Pipeline Aims to Address ...
5 Μαρ 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.
1 Δεκ 2021 · An effective and scalable cure strategy is a top priority for the HIV research field; this Review discusses recent advances, knowledge gaps, and priority research areas for the next 5 years.
10 Ιουλ 2024 · Twice-yearly injections of Lenacapavir showed overwhelming efficacy for preventing HIV infections compared to standard oral preventative HIV medicines, known as pre-exposure prophylaxis (PrEP). Additional trials are ongoing in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.
26 Ιουλ 2023 · Jan. 22, 2020 — Overcoming HIV latency -- induction of HIV in CD4+ T cells that lay dormant throughout the body - is a major step toward creating a cure for HIV. For the first time,...
21 Ιουν 2023 · HIV cure research has entered an era of proof-of-concept testing, with multiple groups seeking to use immunotherapy to control the virus post-antiretroviral therapy (ART).
9 Φεβ 2024 · Understanding the fine-tuned interplay between host immune responses and viral reservoir cells will help to design improved interventions that exploit the immunological vulnerabilities of HIV-1...
